Background: The intravitreal injection of dispase has been shown to be a valuable method for induction of experimental PVR. The goal of the present study was to gain additional information about potential side effects associated with this method. Methods: Twenty-one pigmented rabbits received a single injection of dispase under topical anesthesia to one eye only, contralateral eyes served as untreated control. The animals were injected with doses from 0.045 to 0.065 units of dispase: 8 animals received 0.045 units, 9 animals 0.055 units and 4 animals 0.065 units. Results: Proliferative vitreoretinopathy occurred in 81% of the treated eyes. In 90% cataract formation was observed. Lens luxation was present in 47.3% of the cataract eyes. Conclusion: Intravitreal injection of dispase resulted in the reproducible induction of PVR in addition to cataract formation and lens luxation. Whether these effects may all be associated with a toxic reaction or whether the proliferative changes are solely triggered by endogenous reactions similar to the pathomechanism of human PVR and whether the cataract formation and the lens luxation may be avoided by changing the method of injection require further investigation.

Keywords:
Dispase, Experimental model, Intravitreal injection, Proliferative vitreoretinopathy, Cataract, Zonulolysis
1.
Machemer R: Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol 1978;62:737–740.
2.
Silicone Study Group: Proliferative vitreoretinopathy. Am J Ophthalmol 1985;99:593–595.
3.
Wiedemann P: Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy and retinal degeneration. Surv Ophthalmol 1992;36:373–384.
4.
Rachal WF, Burton TC: Changing concepts of failure after retinal detachment surgery. Arch Ophthalmol 1979;97:480–483.
5.
Sugita G, Tano Y, Machemer R, Abrams G, Claflin A, Fiorentino G: Intravitreal autotransplantation of fibroblasts. Am J Ophthalmol 1980;89:121–130.
6.
Radtke ND, Tano Y, Chandler D, Machemer R: Simulation of massive periretinal proliferation by autotransplantation of retinal pigment epithelial cells in rabbits. Am J Ophthalmol 1981;91:76–87.
7.
Goldaracena MB, Garcia-Layana A, Pastor JC, Saornil MA, de la Fuente F, Gayoso MJ: The role of retinotomy in an experimental rabbit model of proliferative vitreoretinopathy. Curr Eye Res 1997;16:422–427.
8.
Pastor JC, Rodriguez E, Marcos MA, Lopez MI: Combined pharmacologic therapy in a rabbit model of proliferative vitreoretinopathy (PVR). Ophthalmic Res 2000;32:25–29.
9.
Rubsamen PE, Davis PA, Hernandez E, O’Grady GE, Cousins SW: Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol 1994;112:407–413.
10.
Yeo JH, Sadeghi J, Campochiaro PA, Green WR, Glaser BM: Intravitreous fibronectin and platelet-derived growth factor: new model for traction retinal detachment. Arch Ophthalmol 1986;104:417–421.
11.
Lean JS, van der Zee WA, Ryan SJ: Experimental model of proliferative vitreoretinopathy (PVR) in the vitrectomised eye: effect of silicone oil. Br J Ophthalmol 1984;68:332–335.
12.
Irie Y: Neutral protease useful for animal tissue and cell culture. US Patent 3948725, 1976.
13.
Matsumura T, Yamanaka T, Hashizume S, Irie Y, Nitta K: Tissue dispersion, cell harvest and fluid suspension culture by the use of bacterial neutral protease. Jpn J Exp Med 1975;45:377–382.
14.
Green H, Kehinde O, Thomas J: Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc Natl Acad Sci USA 1979;76:5665–5668.
15.
Merkel U, Angermuller S, Merz WE: An enzymatic method for the isolation of mouse Leydig cells. Cell Mol Biol 1990;36:213–224.
16.
Pfeffer B: Improved methodology for cell culture of human and monkey retinal pigment epithelium. Prog Ret Res 1991;10:251–291.
17.
Brem RB, Robbins SG, Wilson DJ, O’Rourke LM, Mixon RN, Robertson JE, Planck SR, Rosenbaum JT: Immunolocalization of integrins in the human retina. Invest Ophthalmol Vis Sci 1994;35:3466–3474.
18.
Heegaard S: Structure of the human vitreoretinal border region. Ophthalmologica 1994;208:82–91.
19.
Jerdan JA, Kao L, Glaser BM: The inner limiting membrane – a modified basement membrane? Invest Ophthalmol Vis Sci 1986;27 (suppl):230.
20.
Tezel TH, V. Del Priore L, Kaplan HJ: Posterior vitreous detachment with dispase. Retina 1998;18:7–15.
21.
Frenzel EM, Neely KA, Walsh AW, Cameron JD, Gregerson DS: A new model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1998;39:2157–2164.
22.
Fastenberg DM, Diddie KR, Sorgente N, Ryan SJ: A comparison of different cellular inocula in an experimental model of massive periretinal proliferation. Am J Ophthalmol 1982;93:559–564.
23.
Kim SH, Kim JH, Cho KS, Kwak JS: Safety of intravitreally injected ciprofloxacin in phakic rabbit eyes. Korean J Ophthalmol 1995;9:12–18.
24.
Hikichi T, Kado M, Yoshida A: Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp Eye Res 2000;70:31–39.
25.
Hikichi T, Kado M, Yoshida A: Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina 2000;20:195–198.
26.
Stenn KS, Link R, Moelmann G, Madri J, Kuklinska E: Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. J Invest Dermatol 1989;93:287–290.
27.
Datiles MB, Kinoshita JH: Pathogenesis of cataracts; in Tasman W, Jaeger EA (eds): Duane’s Clinical Ophthalmology. Philadelphia, Lippincott-Raven, 1995, vol 1(72B), pp 1–14.
28.
Oliveira LB, Tatebayashi M, Mahmoud TH, Blackmon SM, Wong F, McCuen BW 2nd: Dispase facilitates posterior vitreous detachment during vitrectomy in young pigs. Retina 2001;21:324–331.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.